Partners, Health Catalyst partner on population health

Partners HealthCare and Health Catalyst have agreed to share best practices, intellectual property, technology and training in an unprecedented $30 million partnership focused on population health management (PHM).

The Boston-based provider already is invested in Health Catalyst and raised its equity ownership stake in the growing health data warehousing and analytics company. Salt Lake City-based Health Catalyst is investing in money, time and effort in the initiative.

The initiative will enable the development and testing of innovative PHM strategies at Partners and, in collaboration with Health Catalyst, facilitate the transfer of the knowledge generated to other health care providers.

“This agreement with Health Catalyst and our new Center for Population Health will accelerate our care management program and improve outcomes for Partners HealthCare patients, as well as provide the infrastructure and knowledge base for broader outcomes transformation both here and across the country,” said Timothy G. Ferris, MD, senior vice president of Population Health Management for Partners HealthCare, who will lead the new Center of Population Health. “We have made significant progress with population health and care management over the past decade, including using Health Catalyst technology and services over the past few years, and we now believe we can take our efforts to the next level by further leveraging the experience and know-how of both organizations.”

The agreement between Partners HealthCare and Health Catalyst includes four major elements:

  • Health Catalyst and Partners HealthCare will collaborate through the creation of a new Partners HealthCare Center for Population Health. The Center will train Health Catalyst and Partners HealthCare clinical and administrative teams in best practices for care management and population health. Health Catalyst graduates of the program will disseminate these best practices to client healthcare organizations across the country.
  • Health Catalyst is licensing technology, content and analytics innovations that Partners HealthCare, the Massachusetts General Physician Organization and the Brigham and Women’s Physician Organization developed as part of its decade-long care management and population health management programs. Health Catalyst intends to commercialize these innovations to further enhance Partners HealthCare’s population health and care management programs, and to benefit other health systems in their care management and population health initiatives.
  • Partners HealthCare has signed an expanded enterprise-wide technology subscription agreement, giving it access to Health Catalyst’s full suite of technology solutions to accelerate outcomes improvement. In keeping with Health Catalyst’s mission to improve outcomes, a portion of the company’s revenue from the subscription will be tied to the attainment of measurable improvements in Partners HealthCare’s clinical and financial performance.
  • Partners HealthCare is increasing its equity ownership stake in Health Catalyst, after first investing in the company in 2013.
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.